Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
Semnur Pharmaceuticals, a subsidiary of Scilex, plans a business combination with Denali Capital Acquisition Corp. Semnur's lead product, SP-102 (SEMDEXA), a novel non-opioid pain therapy for sciatica, has shown promising Phase 3 trial results.